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Background: Recent studies have shown that miR-372 plays important roles in hepatocellular carcinoma (HCC)
progression. However, results have been conflicting regarding its expression levels and role in HCC.
Methods: RT-PCR and in situ hybridization was used to evaluate miR-372 expression in HCC tissues and cell lines.
The methylation status of neighboring CpG islands upstream of the miR-372 promoter was analyzed by
methylation-specific PCR (MSP). Transfection of miR-372 mimic into HCC cell lines was used to evaluate cellular
proliferation and invasion. Prognostic significance was analyzed by the Kaplan–Meier survival method and Cox
regression.
Results: miR-372 was expressed at lower levels in HCC tissues compared with controls and was related to
tumor metastasis and poor prognosis. Hypermethylation of miR-372 was detected in HCC cell lines and tissues,
and miR-372 expression was restored upon 5-aza-dCyd treatment. Upregulated expression by mir-372 mimic
transfection inhibited proliferation and invasion capacity in HCC cells.
Conclusions: miR-372 may play an important role in hepatic carcinogenesis and may serve as a new target or
method to detect and treat HCC in the future.
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Hepatocellular carcinoma (HCC) is the fifth most
common malignant tumor worldwide with an inci-
dence of approximately 626,000 cases each year [1,2].
In China and Southeast Asia, HCC is highly associated
with viral hepatitis B and cirrhosis [3]. Prognosis of
patients with HCC has improved largely owing to the
development of effective surgical techniques and diag-
nostic methods over recent years. However, long-term
prognosis is still unsatisfactory largely due to the high
recurrence and invasion rates even after resection
(50–70% at 5 years) [4,5].
MicroRNAs (miRNAs) represent a class of endogenous,
highly conserved, small nonprotein-coding RNAs that are* Correspondence: wgzwl@hotmail.com
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unless otherwise stated.approximately 22 nucleotides in length [6]. miRNAs are
expressed in many organisms and function in the regula-
tion of target gene expression via a complex process [7,8].
miR-372 belongs to the Mir-371-372 gene cluster, which
is located on chromosome 19q13.42 [9]. Recent studies
demonstrated that miR-372 regulates the cell cycle, apop-
tosis, invasion, and proliferation in many types of human
cancers. For example, miR-372 promotes cell proliferation
and cell cycle progression, and suppresses apoptosis in
testicular germ cell tumors as well as in a gastric cancer
cell line [10]. Yu et al. [11] identified miR-372 as a prog-
nostic marker for the prediction of cancer relapse and sur-
vival in non-small cell lung cancer patients independent of
stage or histological type. Furthermore, Lai et al. [12] pro-
vided evidence that miR-372 may post-transcriptionally
downregulate the large tumor suppressor homolog 2 in
non-small cell lung cancer patients resulting in tumori-
genesis and proliferation. However, the role of miR-372 inis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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was expressed at high levels in HCC and may exert a
proto-oncogene effect in hepatic carcinogenesis. In con-
trast, our previous study showed opposite results, and
demonstrated that mir-372 was expressed in HCC at low
levels and plays an anti-oncogene role by negatively con-
trolling its target gene ATAD2 [14].
In this study, we used various methods to evaluate
miR-372 expression levels, as well as investigate the
mechanism of its abnormal expression and role in HCC.
Methods
Patient tissue samples and liver cancer cell lines
HCC tissue slice samples were obtained from 120 pa-
tients (51 males and 69 females) diagnosed with HCC
who had undergone a routine hepatic resection in the
First Affiliated Hospital of China Medical University be-
tween January 2007 and January 2009. The follow-up
period for survivors was 5 years. None of the patients
had received preoperative radiotherapy or chemotherapy
prior to surgical resection. A total of 37 paired fresh
specimens, including both tumor tissues and the corre-
sponding paired noncancerous parenchyma, were snap-Figure 1 RT-PCR tested Mir-372 expression in 37 HCC tissues samples
2.96, **P < 0.01). a: ΔCt (U6B minus mir-372) was used to compared the e
vs −12.38 ± 2.96, **P < 0.01); b: CpG islands located approximately 1,200 bfrozen in liquid nitrogen and stored at −70°C immediately
after resection until processing. Histological diagnosis and
differentiation were evaluated independently by three pa-
thologists according to the WHO classification system
[15]. The project protocol was approved by the Institu-
tional Ethics Committee of China Medical University
prior to the initiation of the study. All patients provided
written informed consent for the use of the tumor tissues
for clinical research. The liver cancer cell lines Huh7,
HCCLM3, HepG2, SMMC7721, PLC5, and QGY7701 and
the normal liver cell line LO2 were obtained from Shanghai
Cell Bank (Shanghai, China).RNA preparation and quantitative real-time PCR
Total RNA was extracted from approximately 100 mg of
the 37 paired tissue samples and liver cancer cell lines
using TRIzol reagent ( Invitrogen Company,USA) ac-
cording to the manufacturer’s instructions. The miR-
372 primers were purchased from Takara Company
(Japan). The U6B gene was used as a reference control
for miR-372. The relative levels of gene expression were
represented as ΔCt = Ct gene - Ct reference and theand corresponding normal tissues (−14.89 ± 2.83 vs −12.38 ±
xpression difference between tumor and normal tissues (−14.89 ± 2.83
p upstream of the promoter.
Figure 2 In situ hybridization tested Mir-372 expression in 120 HCC tissue slice samples. a,b,c: showed the staining difference between
tumor and normal tissue slices; d,e,f: showed the different Mir-372 expression levels in tumor tissue slices.
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2−ΔΔCt method [16].
DNA extraction and methylation-specific PCR (MSP)
Genomic DNA was extracted from cell lines and speci-
mens using SDS/proteinase K, followed by phenol-
chloroform extraction and ethanol precipitation. Bisulfite
treatment was performed using the EZ DNA Methylation-
Gold Kit (Zymo Research) according to the manufac-
turer’s instructions. The LO2 normal liver cell line and
peripheral blood treatment with M. Sss I (New England
Biolabs, Ipswich, USA) were used as negative and positive
controls, respectively. A water control was run with every
MSP. The analyst performed the procedures on 3 days.
In situ hybridization
The in situ hybridization kit was purchased from Boster
Company (Wuhan, China) and used according to the
manufacturer’s instructions. Briefly, the tissue slides
were hybridized with 20 ul of 5′-digoxigenin (DIG)
LNA-modified-miR-372-3p. The nucleic acid sequence
is 5′-ACGCTCAAATGTCGCAGCACTTT-3′. Results
were independently scored by two experienced patholo-
gists. The scoring of positive tumor cells was as follows:
0 (0%), 1 (1–10%), 2 (11–50%) and 3 (>50%). The staining
intensity was visually scored as follows: 0 (negative), 1
(weak), 2 (moderate) and 3 (strong). The miR-372 expres-
sion score was calculated from the value of percentpositivity score multiplied by the staining intensity
score. This value ranged from 0 to 12, and the tumors
were classified as follows: negative (−), score 0; lower ex-
pression (1+), score 1–4; moderate expression (2+), score
5–8; and strong expression (3+), score 9–12. In situ
hybridization miR-372 staining was grouped into two cat-
egories: low expression (0/1+) and high expression (2+/3+).
Cell transfection
For RNA transfection, 5 × 104 HUH7 or HCCLM3 cells
were seeded into each well of culture plates and incubated
overnight. When cells were grown to 60–80% confluence,
miR-372 mimic or negative control oligonucleotides
(Genepharma Company) (5 pmol/μl) were transfected
using Lipofectamine® RNAiMAX Reagent (Invitrogen,
USA) according to the manufacturer’s instructions.
Sequences are as follows: miR-372 mimic 5′-AAAGU
GCUGCGACAUUUGAGCGUGCUCAAAUGUCGCA
GCACUUUUU-3′, and miR-372 inhibitor 5′-ACG
CUCAAAUGUCGCAGCACUUU-3′ (both purchased
from Shanghai Genepharma Company). Cells plated in
96-well, 24-well, and 6-well plates were transfected
with 1 μl (5 pmol), 3 μl (15 pmol), and 15 μl (75 pmol)
oligonucleotides, respectively.
Cell cycle analysis
Huh7 or HCCLM3 cells seeded at a density of 5 × 105
per well in 6-well plates were transfected with miR-372
Figure 3 RT-PCR and MSP respectively detected Mir-372 expression and DNA methylation. a: Mir-372 expression levels and DNA
methylation status in HCC cell lines. b; Mir-372 DNA methylation levels in HCC tumor and corresponding normal tissues. (U: unmethylation;
M: methylation; N: corresponding normal tissues; T: tumor tissues; UP: negative controls; MP: positive controls).
Figure 4 The relationship between relative mir-372 expression in 37 cases HCC patients and DNA methylation level in tumor tissues
and corresponding normal tissues. It could be observed the DNA methylation level in tumor tissues was positive correlation with relative mir-
372 expression, and DNA methylation level in normal tissues was negative correlation.
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Figure 5 Four HCC cell lines (HUH7, HCCLM3, SMMC7721, LO2) were treated with 5-aza-dCyd, a methyltransferase inhibitor and the
miRNA expression levels were assayed using TaqMan miRNA PCR. The expression of mir-372 was restored with 5-aza-dCyd treatment in
HUH7 and HCCLM3 cell lines (*P < 0.05,**P < 0.01) and the mir-372 DNA methylation level was inhibited. Treatment with a histone deacetylase
inhibitor, TSA, had no influence on the expression of mir-372 in all four cell lines.
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cells were trypsinized, fixed with 70% ethanol at 4°C,
and washed with PBS. RNase A (100 μL) was added, and
the mixture was incubated in a 37°C water bath for
30 min. Next, 400 μL PI staining solution was added and
samples were incubated at 4°C in the dark for 30 min; a
computer was then used to detect and record the red
fluorescence upon excitation at a wavelength of 488 nm.
CCK8 and colony formation assay
Cells were plated in 96-well plates in media containing
10% FBS at approximately 2,000 cells per well, 24 h after
transfection. Next, 10 μl of CCK8 (thiazolyl blue) solu-
tion was added to each well and samples were incubated
for 1 h at 37°C. The results were quantified spectro-
photometrically using a test wavelength of 450 nm. After
transfection, logarithmic growth phase cells in mono-
layer culture were prepared for the colony formation
assay. Cells were plated in 6-well plates in media con-
taining 10% FBS at approximately 200 cells per well.
Colony formation was then allowed to proceed for 2 w.
Cells were washed with 1 ml of PBS, fixed, stained with
500 μl of 0.1% crystal violet solution for 20 min, and fi-
nally washed three times with 1 ml of water. The fixed
cell colonies were allowed to air dry. The clone forma-
tion rate was calculated.
Cell invasion assay
Huh7 or HCCLM3 cells were infected with miR-372
mimic for 48 h. Cells were then seeded onto a synthetic
basement membrane in the inset of a 24-well culture
plate. In the invasion assay, polycarbonate filters coated
with 50 μL Matrigel (1:9, BD Bioscience) were placed in
a Transwell chamber (Costar). After incubation, filters
were fixed and stained with 0.1% crystal violet solution.
Non-invading cells were removed using a cotton swab,and invading cells on the underside of the filter were
counted with an inverted microscope.
Ethics statement
The project protocol was approved by the Institutional
Ethics Committee of China Medical University prior to
the initiation of the study. All patients provided written
informed consent for the use of the tumor tissues for
clinical research.
Results
miR-372 expression in HCC tissues and cell lines
RT-PCR showed that the mean expression levels of miR-
372 were lower in HCC tissues compared with normal tis-
sues (−14.89 ± 2.83 vs. −12.38 ± 2.96, respectively; P <0.01)
(Figure 1). Of 120 HCC patients, miR-372 was expressed at
low levels in 87 cases (72.5%) according to in situ
hybridization (Figure 2). Furthermore, HUH7 and
HCCLM3 HCC cell lines showed lower expression levels of
miR-372 than HepG2, SMMC7721, PLC5, QGY7701 and
LO2 cells (Figure 3a).
Low expression of mir-372 is related to DNA methylation
To evaluate the mechanism of low expression of miR-
372, we analyzed the upstream sequence of the miR-372
gene promoter and found CpG islands located approxi-
mately 1,200 bp upstream of the promoter. Thus we
speculated that epigenetic changes of the miR-372 gene
by aberrant promoter hypermethylation might be respon-
sible for miR-372 low expression. We next analyzed the
methylation status of miR-372 using MSP in both HCC tis-
sue samples and cell lines. MSP analysis results showed
hypermethylation of miR-372 in HUH7, HCCLM3,
QGY7701, and PLC5 cells and partial methylation in
Smmc7721 and HepG2 cells. However, no methylation was
observed in LO2 cells. The methylation status of mir-372
Table 1 Association between miR-372 expression according to in situ hybridization and conventional clinicopathological
parameters in 120 patients with HCC
Characteristics Number of patients Mir-372 Lowexpression Mir-372 Highexpression P
Total cases 120 87 33
Age (years)
≥50 74 54(72.9%) 20(27.1%) 0.883
<50 46 33(71.7%) 13(28.3%)
Gender
Male 51 37(72.5%) 14(27.5%) 0.992
Female 69 50(72.4%) 19(27.6%)
Tumor size
≥5 cm 51 33(64.7%) 18(35.3%) 0.100
<5 cm 69 54(78.3%) 15(21.7%)
Metastasis
Yes 37 32(86.5%) 5(13.5%) 0.022
No 83 55(66.3%) 28(33.7%)
HBsAg status
Positive 72 54(75%) 18(25%) 0.453
Negative 48 33(68.8%) 15(31.3%)
Tumor differentiation
High 43 29 (67.4%) 14(32.6%) 0.411
Moderate 44 35(79.5%) 9(20.5%)
Poor 33 23(69.7%) 10(30.3%)
Cirrhosis
Yes 73 49(67.1%) 24(32.9%) 0.101
No 47 38(80.9%) 9(19.1%)
Serum AFP
<200 ng/dl 68 53(77.9%) 15(22.1%) 0.127
≥200 ng/dl 52 34(65.4%) 18(34.6%)
Recurrence*
Yes 34 23(67.6%) 11(32.4%) 0.454
No 86 64(74.4%) 22(25.6%)
Tumor stage
I 18 11(61.1%) 7(38.9%) <0.001
II 32 14(43.8%) 18(56.2%)
III 40 36(90%) 4(10%)
IV 30 26(86.7%) 4(13.3%)
Notes: Bold fonts indicate Statistically significant. Recurrence*:follow-up time for five years after therapeutic surgery.
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(Figure 3a).
Among the 37 HCC specimens, 20 cases (54.1%)
showed DNA hypermethylation of miR-372, and par-
tial methylation was observed in 10 cases (27.0%)
cases and 7 cases (18.9%) showed no methylation. In cor-
responding nonmalignant liver tissues, 9 cases (24.3%)showed hypermethylation, and partial methylation was ob-
served in 11 cases (29.7%) cases and 17 cases (45.9%)
showed no methylation. The DNA methylation level in
tumor tissues showed a positive correlation with the
relative miR-372 expression in 37 HCC cases and a
negative correlation in normal tissues. This indicated
that DNA methylation level not only affected miR-372
Table 2 COX regeression regression analysis on the relationship of clinicopathologic characteristics and prognosis
Characteristics Univariate Multivariate
HR CI(95%) P HR CI(95%) P
Mir-372 1.751 1.178-2.603 0.006 1.872 1.210-2.896 0.005
Age 0.982 0.671-1.437 0.924
Gender 1.113 0.729-1.698 0.620
Tumor stage 1.098 0.810-1.488 0.547
Tumor differentiation 1.080 0.800-1.456 0.616
Metastasis 1.942 1.319-2.861 0.001 1.811 1.131-2.898 0.013
Tumor size 1.334 0.896-1.986 0.156
Serum AFP 2.280 1.482-3.505 0.0001 1.99 1.231-3.228 0.005
Cirrhosis 1.310 0.894-1.921 0.166
Notes: Bold fonts indicate Statistically significant.
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relative miR-372 expression difference between tumor
and the corresponding normal tissues (Figure 4).
We then assessed the effects of demethylation on the
expression of miR-372. Four HCC cell lines (HUH7,
HCCLM3, SMMC7721, LO2) were treated with 5-aza-
dCyd, a methyltransferase inhibitor, and the miRNA ex-
pression levels were assayed using TaqMan miRNA
PCR. The expression of miR-372 was restored with 5-
aza-dCyd treatment in HUH7 and HCCLM3 cell lines
and the miR-372 DNA methylation level was inhibited
(Figure 5), suggesting that aberrant DNA methylation
suppressed the expression of mir-372. Treatment with a
histone deacetylase inhibitor, TSA, had no influence on
the expression of miR-372 in all four cell lines (Figure 5).
These findings suggest that histone deacetylation may
not contribute to the transcriptional repression of miR-372.Figure 6 Overall survival of HCC patients in relation to mir-372
expression levels according to in situ hybridization. Survival of
HCC patients with high mir-372 expression versus low expression.miR-372 expression was related to tumor metastasis and
poor prognosis in HCC
We next analyzed the association between the miR-372
expression and various clinicopathological factors of the
HCC patients. Interestingly, the expression levels of
miR-372 were significantly lower in HCC tissues with
advanced TNM stage compared with those with early
TNM stage (P = 0.003) and miR-372 low expression tissues
had more tumor metastasis (P < 0.001, Table 1). Patients
with lower miR-372 expression had poorer prognosis. The
overall survival was significantly lower in patients with low
miR-372 expression than in patients with high miR-372
expression (P = 0.004) (Figure 6). In addition, multivariate
analysis demonstrated that miR-372 levels, metastasis and
AFP status were significant prognostic factors for HCC pa-
tients (Table 2).
Ectopic expression of miR-372 inhibits cancer cell line
invasion
Of the seven liver cancer cell lines analyzed, Huh7 and
HCCLM3 cells demonstrated relatively lower levels of
miR-372 expression. Subsequently, these two cell lines
were used to study the function of miR-372. We found
that enhancement of the expression level of miR-372 in
Huh7 and HCCLM3 cells could significantly inhibit inva-
sion and migration abilities. Transwell chamber assay re-
sults showed that the number of invasive and migrated
cells in the miRNA overexpression group (31 ± 6 and 39 ±
8, respectively) was significantly lower than that in the
negative control group (62 ± 11 and 81 ± 14, respectively)
in Huh7 cells. The same trend was also observed in
HCCLM3 cells (30 ± 9 and 34 ± 7 vs. 67 ± 12 and 77 ± 16,
respectively P < 0.01) (Figure 7). Because miR-372 could
promote cell proliferation,so in order to eliminate strong
effect on cell growth in Transwell assay we used the inva-
sion score by calculating cell count in invasion assay di-
vided by that of migration assay.Results showed the
invasion score in miRNA overexpression group was
Figure 7 Transwell assays of Huh7 and HCCLM3 cells transfected with neg.control and mir-372 mmic:mir-372 up-regulation had a
measurable inhibitory effect on cell invasion in both cell lines.
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Figure 8 Mir-372 expression levels could affect cellular invasion and proliferation in HUH7, HCCLM3 and SMMC7721 cells. a: Invasion
score was that the cell count in invasion assay divided by that of migration assay. b: The CCK8 assay was performed after mir-372 mimic and
inhibitor treatment: A reduction of absorbance was observed in HUH7 and HCCLM3 (*P < 0.05); absorbance increased in SMMC7721 (*P < 0.05).
Wu et al. BMC Cancer  (2015) 15:182 Page 9 of 12significantly lower than that in the negative control group
(71.8 ± 5.8% VS 82 ± 5.2% in Huh7 cells, P= 0.036;80.4 ±
5.8% VS 86.8 ± 4.6% in HCCLM3 cells, P= 0.015)(Figure 8a).
To evaluate the function of endogenous miR-372, we
downregulated mir-372 expression in SMMC7721 cells
(mir-372 high expression) by mir-372 inhibitor transfec-
tion, and found that cellular invasion and migration abil-
ities were enhanced (invasion and migration of negative
control group: 46 ± 6 and 59 ± 9, respectively, vs. mir-372
inhibitor group: 74 ± 13 and 86 ± 18, P < 0.05) (Figure 7).
The invasion score in Neg.cont was lower than miR-372
inhibitor group (75.6 ± 4.3% VS 86.4 ± 3.9%, P =0.038)
(Figure 8a).
Ectopic expression of miR-372 inhibits cancer cell
proliferation
A significant reduction in the proliferation rate was ob-
served by CCK8 assays 3 d after transfection with the
miR-372 mimic compared with the negative control
(Figure 8b). The effect of miR-372 on the cell cycle was
tested using flow cytometry analysis. In Huh-7 cells,
miR-372-overexpressed cells showed an increase in the
number of cells in G1 phase (59.12%) and S phase
(24.17%) compared with the negative control (G1,
45.63%; S, 36.76%). In HCCLM3 cells, miR-372-
overexpression showed an increase in the number of
cells in G1 phase (63.37%) and S phase (18.98%) com-
pared with the negative control (G1, 52.14%; S, 33.59%)(Figure 9). Our results revealed that miR-372 could in-
hibit cell proliferation by blocking G1/S phase.
Colony formation assay results in Huh-7 cells showed
that the number of cells in the miR-372-overexpression
group was significantly lower than that in the negative
control group (123 ± 15 vs. 37 ± 9; P < 0.001). In
addition, in HCCLM3 cells, the number of cells in the
miR-372-overexpression group was significantly lower
compared with the negative control group (104 ± 22 vs.
40 ± 11, P < 0.001) (Figure 10).
Moreover, downregulating mir-372 expression in
SMMC7721 cells by miR-372 inhibitor transfection pro-
moted proliferation as shown in CCK8 and colony for-
mation assays (Figures 8b and 10). However, we did not
find any alteration in cell cycle by flow cytometry
analyses.
Discussion
Many miRNAs have been shown to play important roles
in regulating gene expression by mRNA cleavage or
translational repression in a variety of model systems
[17-19]. Profiling of miRNA expression showed that the
majority of miRNAs are downregulated in tumors com-
pared with normal tissues, such as miR-128 in glioma
tissues [20] and miR-145 in human breast cancer [21].
Recent evidence suggests that miR-372 is a novel candi-
date tumorigenesis oncogene and possibly a therapeutic
target in gastric cancer, non-small cell lung cancer,
Figure 9 Transfecting mir-372 mimic reduced Huh7 and HCCLM3 cell proliferation and led to a G1 phase cell cycle arrest.
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ever, it functions as an anti-tumor factor in cervical can-
cer [22]. Thus, miR-372 might serve different functions
in different cellular environments by acting on different
target genes.
The oncogene ATAD2 is a member of the AAA+
ATPase family of proteins that contains both a bromo-
domain and an ATPase domain, and the gene maps to
chromosome 8q24 in a region that is frequently amplified
in cancer [23]. ATAD2 promotes cellular proliferation and
invasion by regulating the expression of downstream
genes such as APC and CTNNA1 [14], both of which
could play an important role in the development of HCC
[24-26]. ATAD2 also targets PTCH1 [27], one of the key
genes in the Hedgehog pathway, and regulates prolifera-
tion and differentiation in hepatic carcinogenesis. We pre-
viously identified miR-372 as a likely functional upstream
target of ATAD2 in HCC using a luciferase reporter assay.
In this study, we pursued the molecular function of miR-
372 in liver cancer cells.
miR-372 belongs to the miR-371-373 gene cluster,
which also includes miR-93 and miR-302a [28]. These
miRNAs play an important role in the development of
many types of human malignant tumors. However,reports have been conflicting regarding miR-372 expres-
sion levels in HCC, so in the current study we tested
miR-372 expression not only by RT-PCR but also by in
situ hybridization. Results from both approaches showed
that miR-372 was expressed at low levels in HCC. We
identified CpG islands upstream of the miR-372 pro-
moter and speculated that aberrant promoter hyperme-
thylation might be responsible for miR-372 low
expression. The methylation status of neighboring CpG
islands of mir-372 was tested by MSP both in HCC tis-
sue samples and cell lines. MSP and RT-PCR showed
the DNA methylation levels of miR-372 were signifi-
cantly higher and the expression of miR-372 was signifi-
cantly lower in tumors compared with their non-tumor
tissue counterparts. Furthermore, DNA methylation sta-
tus was related with the expression levels by Spearman
rank analysis, suggesting that the expression of miR-372
was probably induced by aberrant DNA methylation.
Moreover, in HCC cell lines with low expression of miR-
372 (Huh7 and HCCLM3), treatment with 5-aza-dCyd
could restore miR-372 expression but no changes were
observed with TSA. Thus, this data suggests that aber-
rant promoter hypermethylation might induce the epi-
genetic silencing of miR-372 in HCC.
Figure 10 Clonogenic assays were performed with HUH7/HCCLM3 cells (magnification × 10). The number of colonies formed by cells
treated with mir-372 mimic was far fewer than that of neg.cont-treated cells (P < 0.05).
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lines led to a G1 phase cell cycle arrest and reduced cell
growth/proliferation. Similar results were also observed
in CCK8 and colony formation assays. In addition,
mimic-mediated miR-372 could significantly inhibit cell
invasion in transwell chamber assays. Taken together,
these data provide evidence that miR-372 is not only im-
portant in HCC cell proliferation but is also involved in
cell invasion. Further analyses indicated that the low ex-
pression of miR-372 in the HCC tissues was negatively
correlated with TNM stage and metastasis. These results
demonstrated that the upregulation of miR-372 in HCC
might play an important role in repressing malignant tu-
mors. Similar results were also observed in cervical can-
cer, in which miR-372 was expressed at low levels and
may downregulate CDK2 and cyclin A1 to control cellgrowth and cell cycle progression [22]. Furthermore, we
found that the low expression of miR-372 in HCC was a
strong and independent predictor of longer overall
survival.Conclusions
In summary, here we clarified the anti-tumor role of
miR-372 in HCC by four pieces of experimental evi-
dence: (a) miR-372 is downregulated in HCC; (b) aber-
rantly high DNA methylation in the miR-372 gene
promoter induced the epigenetic silencing of miR-372;
(c) mir-372 can inhibit the proliferative and invasive cap-
acity in HCC cell lines; and (d) miR-372 expression was
related with tumor metastasis and poor prognosis in
HCC.
Wu et al. BMC Cancer  (2015) 15:182 Page 12 of 12These findings indicate that miR-372 plays an important
role in hepatic carcinogenesis and is closely related to the
outcome after HCC surgery. This may provide a new tar-
get or method to detect and treat HCC in the future.
Therefore, further studies are still need to determine the
precise mechanism underlying the role of miR-372 in
HCC progression.
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